Sbir phase i topic 339 systemic targeted radionuclide therapy for cancer treatment period of performance: 09/22/2015 - 06/21/2016

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201500050C
Awardee
Awarding agency
Obligated
$300,000

Award facts

Contract value 100% obligated
$300,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 11 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Los Alamos, NM 87544, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $300,000

About this award

This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Icagen, Inc. for a Small Business Innovation Research (SBIR) Phase I project titled "SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT". The period of performance is from September 22, 2015 to June 21, 2016, with an ultimate completion date of September 30, 2016. This contract was not set aside for a specific business size or type. The goal of this SBIR Phase I project is to develop targeted radionuclide therapies for cancer treatment.

Quick answers

Who was awarded contract HHSN261201500050C?

HHSN261201500050C was awarded to Icagen, Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2015.

How much is contract HHSN261201500050C worth?

The government has obligated $300,000 on HHSN261201500050C.

Was contract HHSN261201500050C competed?

The extent of competition for HHSN261201500050C was full and open competition. The government received 11 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award